BeOne Medicines is a global oncology-focused biotechnology company developing and commercializing cancer treatments. Its portfolio includes the BTK inhibitor BRUKINSA, the PD-1 inhibitor TEVIMBRA, and a pipeline of targeted therapies and immuno-oncology candidates. The company conducts clinical development and commercialization internationally, with particular expertise in hematologic cancers and solid tumors.
BeOne Medicines Ltd ADR (ONC) has a MarketKingdoms composite score of 73.4 (B+), an B-range rating. It ranks 109th of 1,866 covered companies, 4th of 78 in Healthcare (sector average 64.4) and 2nd of 12 in Biotechnology. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 99 (Healthcare average 78) and Expansion (growth) at 93 (Healthcare average 50). Its weakest lenses are Price (valuation) at 25 (sector average 50) and Trend (momentum) at 60 (sector average 50).
| Lens | Type | ONC | Healthcare average | Biotechnology average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 85 | 79 | 78 | 83rd |
| KPI momentum | Research signal | 99 | 78 | 75 | 100th |
| Catalyst watch | Research signal | 73 | 74 | 74 | 41st |
| Price (valuation) | Fundamental lens | 25 | 50 | 30 | 18th |
| Expansion (growth) | Fundamental lens | 93 | 50 | 64 | 97th |
| Quality (profitability) | Fundamental lens | 75 | 50 | 55 | 86th |
| Trend (momentum) | Fundamental lens | 60 | 50 | 48 | 62nd |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -26.6%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 1.70, sector beta 1.04, industry beta -0.01; the factor model explains 40% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 74.9 | B+ | -17.8% |
| Regeneron Pharmaceuticals Inc. (REGN) | 72.7 | B+ | +7.7% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | -7.5% |
| argenx SE ADR (ARGX) | 68.0 | B | -27.3% |
| Incyte Corporation (INCY) | 68.0 | B | -18.8% |
| Alnylam Pharmaceuticals Inc. (ALNY) | 61.4 | B- | -18.1% |
| Bio-Techne Corporation (TECH) | 60.4 | B- | -22.2% |
| Insmed Inc. (INSM) | 60.0 | B- | -48.5% |
BeOne Medicines Ltd ADR financial statements · Healthcare sector ranking · Biotechnology industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.